Nonalcoholic Steatohepatitis (NASH) is the progressive form of Nonalcoholic Fatty Liver Disease (NAFLD), wherein excessive fat deposition causes inflammation and damage to the liver, eventually leading to cirrhosis and increasing risk of liver failure and hepatocellular carcinoma in some cases.

The report titled “Global Nonalcoholic Steatohepatitis Market- Growth, Future Prospects and Competitive Analysis, 2023–2030” offers strategic insights into the Nonalcoholic Steatohepatitis market along with the market size and estimates for the duration 2023 to 2030. The research study covers in-depth analysis of market segments based on drug type, and different geographical region.

In order to help strategic decision makers, the report also includes competitive profiling of the leading players in global Nonalcoholic Steatohepatitis market, attractive investment proposition and market positioning of key manufacturers sections.

Market size and forecast for these regional and country level markets are presented in this study for the period 2020-2030. Market growth rates for the forecast period 2023-2030 are also included in this report, considering 2021 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as pipeline analysis, market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global Nonalcoholic Steatohepatitis market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global Nonalcoholic Steatohepatitis market. This report concludes with company profiles section that highlights major information about the key players engaged in global Nonalcoholic Steatohepatitis market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report. 

Thus, the research study provides a holistic view of the global Nonalcoholic Steatohepatitis market, offering market size and estimates for the period from 2023 to 2030, keeping in mind the above-mentioned factors.

Nonalcoholic Steatohepatitis (NASH) is the progressive form of Nonalcoholic Fatty Liver Disease (NAFLD), wherein excessive fat deposition causes inflammation and damage to the liver, eventually leading to cirrhosis and increasing risk of liver failure and hepatocellular carcinoma in some cases. NASH affects around 2-5% of Americans and is considered to be one of the foremost causes of liver transplantation. Currently management of NASH includes lifestyle changes such as healthy diet, weight reduction and physical activity. Despite of growing treatment need there are no approved therapeutic for NASH. Some drugs are prescribed off-label such as Metformin which is used in type-2 diabetes and NASH. However, NASH therapeutics exhibit a lucrative pipeline with more than 20 drug candidates undergoing Phase II clinical trials. The most promising drug anticipated to enter the NASH market in the near future is Elafibranor (Genfit) and Obeticholic Acid (Intercept) which are undergoing phase III trials. Many pharma giants Allergan, Gilead Sciences, Novo Nordisk and Bristol-Myers Squibb are developing drugs for NASH which further boost the NASH market during the future period.

For the purpose of this study, the global non-alcoholic steatohepatitis market is segmented into regional markets such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. According to the British Liver Trust, Non-Alcoholic Fatty Liver Disease (NAFLD) is considered to be the most common liver problem in the Western world, affecting 20-30% of the population. North America held the largest share in the global non-alcoholic steatohepatitis market. In U.S. more than 25% of the population is affected by NAFLD as mentioned by the America Liver Foundation. Moreover, the rate of obesity is increasing rapidly in children and adult in the U.S. which is a primary risk factor for NASH. Furthermore, aggressive research and clinical trials in the region would further boost the non-alcoholic steatohepatitis market. Asia Pacific is one of the fastest growing NASH market due to alarming increase in the obesity rates in the region due to rising lifestyle changes. Moreover, the increasing number of research & development and supportive regulations are favouring the growth of non-alcohol steatohepatitis market.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Non-Alcoholic Steatohepatitis market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Non-Alcoholic Steatohepatitis market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Non-Alcoholic Steatohepatitis market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Non-Alcoholic Steatohepatitis market?
• Which is the largest regional market for Non-Alcoholic Steatohepatitis market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Non-Alcoholic Steatohepatitis market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Non-Alcoholic Steatohepatitis market worldwide?